Ignite Creation Date:
2024-05-06 @ 8:15 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06312943
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-03-15
First Post:
2024-01-08
Brief Title:
Translating Articular Biomarkers Into Diagnoses
Sponsor:
Assistance Publique - Hôpitaux de Paris
Organization:
Assistance Publique - Hôpitaux de Paris
Study Overview
Official Title:
Translating Articular Biomarkers Into Diagnoses
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ARTBioSes
Brief Summary:
Early diagnosis is a key factor in the prevention and management of rheumatic diseases Rheumatic diseases are classically diagnosed based on criteria combining clinical biological and radiological features However in up to 20 of the cases diagnoses remain unstated and underlying rheumatic diseases unclassified which might lead to delayed specific treatment and unfavourable clinical outcomes In addition conventional methods could lack sensitivity and specificity for early diagnosis Biological samples are attractive targets for the early detection of articular damage because they allow for collection of multiple levels of information from the clinic and the laboratory Biological samples most frequently collected from patients with rheumatic diseases are synovial fluid by joint aspiration blood by venous puncture and tissue specimen by surgery The investigators hypothesize that in challenging situations novel biomarkers detected from synovial fluid or articular tissues using both conventional eg histology immunodetection PCR and innovative eg Raman spectroscopy nanospectroscopy laboratory tests may help refining diagnosis and better classifying patients with rheumatic diseases
Detailed Description:
Early diagnosis is a key factor in the prevention and management of rheumatic diseases Rheumatic diseases are classically diagnosed based on criteria combining clinical biological and radiological features However in up to 20 of the cases diagnoses remain unstated and underlying rheumatic diseases unclassified which might lead to delayed specific treatment and unfavourable clinical outcomes In addition conventional methods could lack sensitivity and specificity for early diagnosis Biological samples are attractive targets for the early detection of articular damage because they allow for collection of multiple levels of information from the clinic and the laboratory Biological samples most frequently collected from patients with rheumatic diseases are synovial fluid by joint aspiration blood by venous puncture and tissue specimen by surgery The investigators hypothesize that in challenging situations novel biomarkers detected from synovial fluid blood or articular tissues using both conventional eg histology immunodetection PCR and innovative eg Raman spectroscopy nanospectroscopy laboratory tests may help refining diagnosis and better classifying patients with rheumatic diseases
Synovial fluid is primarily composed of water proteins proteoglycans glycosaminoglycans lipids small inorganic salts and metabolites such as amino acids or sugars Individual synovial fluid components may often perform multiple functions For example hyaluronic acid maintains the complex viscoelastic properties of synovial fluids and regulates the biological activity of advanced glycation end-products cytokines and enzymes associated with osteoarthritis Normal joint function is dependent on the status of synovial fluid composition especially considering the large interaction between the individual components Although conventional laboratory tests have been used by rheumatologists for the past 50 years they provide limited quantitative data and cannot specifically describe the biochemical and chemical changes such as alterations in protein composition and proteomic profile undergone by synovial fluids in arthritic joints Measurements that reflect the entire synovial fluid chemical biological or viscoelastic profile could be interesting additional tools An example of innovative measurement technique is Raman spectroscopy that can be used to detect changes in synovial fluid from patients with rheumatic diseases Raman band intensity ratios vary significantly in spectra collected from synovial fluid in patients with radiological evidence of osteoarthritis damage Changes to the protein secondary structure could be used as general marker of chemical changes in synovial fluid and that these changes can be associated with radiographic scoring of knee damage Other publications focused on the Raman analysis of crystals extracted from synovial fluids Our group developped Surface Enhanced Raman Spectroscopy SERS using nanoparticles that might be more sensitive than conventional Raman spectroscopy in characterizing biofluids especially the entire synovial fluid and deciphering specific rheumatic disease spectral signatures
Blood biomarkers have long been used for the diagnosis and follow-up of rheumatic diseases They are mainly markers of auto-immunity inflammation cartilage degradation or bone remodelling
Articular tissues include articular cartilage bone meniscus synovial membrane fat tendons ligaments muscles They are obtained during surgery Their analysis is precious to characterize auto-immunity inflammation cartilage degradation or bone remodelling local status and to study local activation of cellular and molecular pathways of interest using conventional techniques of cellular and molecular biology
Synovial fluid is primarily composed of water proteins proteoglycans glycosaminoglycans lipids small inorganic salts and metabolites such as amino acids or sugars Individual synovial fluid components may often perform multiple functions For example hyaluronic acid maintains the complex viscoelastic properties of synovial fluids and regulates the biological activity of advanced glycation end-products cytokines and enzymes associated with osteoarthritis Normal joint function is dependent on the status of synovial fluid composition especially considering the large interaction between the individual components Although conventional laboratory tests have been used by rheumatologists for the past 50 years they provide limited quantitative data and cannot specifically describe the biochemical and chemical changes such as alterations in protein composition and proteomic profile undergone by synovial fluids in arthritic joints Measurements that reflect the entire synovial fluid chemical biological or viscoelastic profile could be interesting additional tools An example of innovative measurement technique is Raman spectroscopy that can be used to detect changes in synovial fluid from patients with rheumatic diseases Raman band intensity ratios vary significantly in spectra collected from synovial fluid in patients with radiological evidence of osteoarthritis damage Changes to the protein secondary structure could be used as general marker of chemical changes in synovial fluid and that these changes can be associated with radiographic scoring of knee damage Other publications focused on the Raman analysis of crystals extracted from synovial fluids Our group developped Surface Enhanced Raman Spectroscopy SERS using nanoparticles that might be more sensitive than conventional Raman spectroscopy in characterizing biofluids especially the entire synovial fluid and deciphering specific rheumatic disease spectral signatures
Blood biomarkers have long been used for the diagnosis and follow-up of rheumatic diseases They are mainly markers of auto-immunity inflammation cartilage degradation or bone remodelling
Articular tissues include articular cartilage bone meniscus synovial membrane fat tendons ligaments muscles They are obtained during surgery Their analysis is precious to characterize auto-immunity inflammation cartilage degradation or bone remodelling local status and to study local activation of cellular and molecular pathways of interest using conventional techniques of cellular and molecular biology
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2022-A02170-43 | OTHER | France Ministry of Health | None |